Evidence map›Paper›PMID 32295593›Full record

Trial reportRespiratory research2020

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.

Henrik Watz, Jens M Hohlfeld, Dave Singh, Jutta Beier, Zuzana Diamant, Jinming Liu, Shucheng Hua, Khalid Abd-Elaziz, Pascale Pinot, Ieuan Jones and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIComparative StudyLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03063086 (A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03063086 phase2completednot on this map

A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma

TypeinterventionalSponsorNovartis PharmaceuticalsRan2017 to 2018Enrolled116ConditionsAsthmaArmsQVM149 150/50/80 μg o.d., QVM149 150/50/160 μg o.d., salmeterol/fluticasone FDC 50/500 μg b.i.d.
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 6 countries.

Henrik WatzPulmonary Research Institute at LungenClinic Grosshandorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Woehrendamm 80, 22927, Grosshansdorf, Germany. h.watz@pulmoresearch.de.
Jens M HohlfeldFraunhofer Institute of Toxicology and Experimental Medicine and Respiratory Medicine of Hannover Medical School, Biomedical Research in End-Stage and Obstructive Lung Disease (BREATH), German Center for Lung Research (DZL), Hannover, Germany.
Dave SinghMedicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
Jutta BeierInsaf Respiratory Research Institute, Biebricher Allee 34, 65187, Wiesbaden, Germany.
Zuzana DiamantDepartment of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, 221 85, Lund, Sweden.
Jinming LiuShanghai Pulmonary Hospital, Shanghai, China.
Shucheng HuaThe First Hospital of Jilin University, Changchun City, Jilin Province, China.
Khalid Abd-ElazizQPS-Netherlands, Groningen, The Netherlands.
Pascale PinotNovartis Institutes for Biomedical Research, Basel, Switzerland.
Ieuan JonesNovartis Pharma AG, Basel, Switzerland.
Hanns-Christian TillmannNovartis Institutes for Biomedical Research, Basel, Switzerland.
Novartis (Switzerland) · CHGerman Center for Lung Research · DEJilin University · CNLund University · SEManchester University NHS Foundation Trust · GBMedizinische Hochschule Hannover · DENovartis Institutes for BioMedical ResearchQPS (Netherlands) · NLRespiratory Research Institute · DEShanghai Pulmonary Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indacaterol (IND; 150 μg), glycopyrronium (GLY; 50 μg) and mometasone furoate (MF; 160 μg [high-dose ICS] and 80 μg [medium-dose ICS]) have been formulated as a once-daily (o.d.) fixed-dose combination treatment delivered via the Breezhaler® device for the treatment of patients with asthma. In this randomized (n = 116), double-blind, double-dummy, active comparator-controlled, three-period cross-over study we evaluated the benefit of o.d. IND/GLY/MF versus twice daily (b.i.d.) salmeterol/fluticasone propionate combination (SFC; 50/500 μg; high-dose ICS) treatment (NCT03063086). Overall, 107 patients completed the study. The study met its primary objective by demonstrating superiority of o.d. IND/GLY/MF at medium and high-dose ICS over b.i.d. SFC (high-dose ICS) in peak FEV

Indexed as

AdolescentAdultAgedAsthmaBronchodilator AgentsCross-Over StudiesDouble-Blind MethodDrug CombinationsFemaleFluticasone-Salmeterol Drug CombinationHumansIndansMaleMiddle AgedMometasone FuroateQuinolonesBronchodilator AgentsDrug CombinationsFluticasone-Salmeterol Drug Combinationindacaterol acetate-mometasone furoate drug combinationIndansMometasone FuroateQuinolonesAsthmaGlycopyrroniumIndacaterolMometasone Furoate

Identifiers

PMID32295593
PMCPMC7160900
OpenAlexW3016929521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.